Abstract | OBJECTIVE: DATA SOURCES: Citations in Google Scholar, PubMed, and Web of Science from January 1, 2005, to March 25, 2013, were identified using nepafenac and cataract as search terms. STUDY SELECTION AND DATA EXTRACTION: The literature search was limited to human studies published in English. Three trials that compared nepafenac with other nonsteroidal antiinflammatory drugs ( NSAIDs) were included. DATA SYNTHESIS: CONCLUSIONS: The 2 nepafenac products appear to be equally efficacious, with a slightly increased adverse event rate in patients using the 0.3% versus 0.1% formulation. Head-to-head clinical trials that compare the 0.3% product with the 0.1% product or other commercially available NSAIDs are unavailable.
|
Authors | Benjamin M Jones, Michael W Neville |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 47
Issue 6
Pg. 892-6
(Jun 2013)
ISSN: 1542-6270 [Electronic] United States |
PMID | 23715071
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Benzeneacetamides
- Phenylacetates
- nepafenac
|
Topics |
- Administration, Topical
- Animals
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage)
- Benzeneacetamides
(administration & dosage)
- Cataract Extraction
(adverse effects)
- Clinical Trials as Topic
(methods)
- Humans
- Pain, Postoperative
(diagnosis, drug therapy, epidemiology)
- Phenylacetates
(administration & dosage)
|